Dose-dependent toxicity can be predicted from _______ and _______ studies.

Dose-dependent toxicity can be predicted from _______ and _______ studies.

• A. In-vivo; preclinical
• B. In-vitro; preclinical
• C. Epidemiological; postmarketing
• D. In-silico; clinical trials

Answer: (B)

The main idea is that predicting dose-dependent toxicity relies on how a substance behaves as the dose changes, using controlled models that show how toxicity scales. In vitro studies provide direct, cellular-level dose–response data, uncovering cytotoxic effects and mechanisms and yielding metrics like concentration thresholds that cause harm. Preclinical studies extend this to a whole-organism context, revealing organ-specific toxicities, pharmacokinetics, and safe exposure levels (such as NOAEL or MTD) to estimate how much exposure would cause adverse effects in a living system. Together, these two kinds of data form the basis for anticipating how increasing dose could translate into toxicity in humans and for setting safety margins before human use. Epidemiological and postmarketing data track real-world toxicities after people have been exposed, which is crucial for detecting adverse effects in practice but not as the primary tool for predicting risk during the development phase. In-silico methods and clinical trials play supporting roles—computational predictions can aid screening, and clinical trials provide safety information in humans after substantial preclinical work—but the foundational prediction of dose-dependent toxicity typically relies on in vitro and preclinical studies.

The main idea is that predicting dose-dependent toxicity relies on how a substance behaves as the dose changes, using controlled models that show how toxicity scales. In vitro studies provide direct, cellular-level dose–response data, uncovering cytotoxic effects and mechanisms and yielding metrics like concentration thresholds that cause harm. Preclinical studies extend this to a whole-organism context, revealing organ-specific toxicities, pharmacokinetics, and safe exposure levels (such as NOAEL or MTD) to estimate how much exposure would cause adverse effects in a living system. Together, these two kinds of data form the basis for anticipating how increasing dose could translate into toxicity in humans and for setting safety margins before human use.

Epidemiological and postmarketing data track real-world toxicities after people have been exposed, which is crucial for detecting adverse effects in practice but not as the primary tool for predicting risk during the development phase. In-silico methods and clinical trials play supporting roles—computational predictions can aid screening, and clinical trials provide safety information in humans after substantial preclinical work—but the foundational prediction of dose-dependent toxicity typically relies on in vitro and preclinical studies.